Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Penserra Capital Management significantly reduced its stake in Vertex Pharmaceuticals, dropping 81% of its shares in the ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...